Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19

While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19 has generated concerns in the early phase of the pandemic because of possible arrhythmogenic effects in relation to QTc interval prolongation. Indeed, some of these drugs have been historically ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiavone, Marco, Gasperetti, Alessio, Gherbesi, Elisa, Bergamaschi, Luca, Arosio, Roberto, Mitacchione, Gianfranco, Viecca, Maurizio, Forleo, Giovanni B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556572/
https://www.ncbi.nlm.nih.gov/pubmed/35221089
http://dx.doi.org/10.1016/j.ccep.2021.10.009
_version_ 1784592195731324928
author Schiavone, Marco
Gasperetti, Alessio
Gherbesi, Elisa
Bergamaschi, Luca
Arosio, Roberto
Mitacchione, Gianfranco
Viecca, Maurizio
Forleo, Giovanni B.
author_facet Schiavone, Marco
Gasperetti, Alessio
Gherbesi, Elisa
Bergamaschi, Luca
Arosio, Roberto
Mitacchione, Gianfranco
Viecca, Maurizio
Forleo, Giovanni B.
author_sort Schiavone, Marco
collection PubMed
description While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19 has generated concerns in the early phase of the pandemic because of possible arrhythmogenic effects in relation to QTc interval prolongation. Indeed, some of these drugs have been historically associated with QT prolongation and Torsade de Point, a potentially lethal ventricular arrhythmia, and their first-time use on a very large scale has raised several concerns in the scientific community. This work aims to summarize the underlying arrhythmogenic mechanisms related to the use of potentially QT-prolonging drugs used during the pandemic to treat COVID-19.
format Online
Article
Text
id pubmed-8556572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85565722021-11-01 Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19 Schiavone, Marco Gasperetti, Alessio Gherbesi, Elisa Bergamaschi, Luca Arosio, Roberto Mitacchione, Gianfranco Viecca, Maurizio Forleo, Giovanni B. Card Electrophysiol Clin Article While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19 has generated concerns in the early phase of the pandemic because of possible arrhythmogenic effects in relation to QTc interval prolongation. Indeed, some of these drugs have been historically associated with QT prolongation and Torsade de Point, a potentially lethal ventricular arrhythmia, and their first-time use on a very large scale has raised several concerns in the scientific community. This work aims to summarize the underlying arrhythmogenic mechanisms related to the use of potentially QT-prolonging drugs used during the pandemic to treat COVID-19. Elsevier Inc. 2022-03 2021-10-30 /pmc/articles/PMC8556572/ /pubmed/35221089 http://dx.doi.org/10.1016/j.ccep.2021.10.009 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Schiavone, Marco
Gasperetti, Alessio
Gherbesi, Elisa
Bergamaschi, Luca
Arosio, Roberto
Mitacchione, Gianfranco
Viecca, Maurizio
Forleo, Giovanni B.
Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title_full Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title_fullStr Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title_full_unstemmed Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title_short Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
title_sort arrhythmogenic risk and mechanisms of qt-prolonging drugs to treat covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556572/
https://www.ncbi.nlm.nih.gov/pubmed/35221089
http://dx.doi.org/10.1016/j.ccep.2021.10.009
work_keys_str_mv AT schiavonemarco arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT gasperettialessio arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT gherbesielisa arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT bergamaschiluca arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT arosioroberto arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT mitacchionegianfranco arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT vieccamaurizio arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19
AT forleogiovannib arrhythmogenicriskandmechanismsofqtprolongingdrugstotreatcovid19

Ejemplares similares